Ten post jest także dostępny w języku: polski
Ryvu Therapeutics (formerly Selvita), a Polish biotechnology company, is expanding its plans for R&D projects. By the end of 2022, the company intends to have at least three projects in the clinical phase.
SEL120 in Phase II in two years’ time
The key drug in Ryvu’s portfolio is SEL120, designed to treat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). It is the first in its class low-molecular selective inhibitor of CDK8 kinase and its closely related CDK19 serine kinase. The Phase I clinical trial of SEL120 Ryvu is scheduled to be completed in mid-2021, one year later the drug is to be introduced to Phase II.
SEL120 was administered to the first patient in September 2019. Currently, the Phase 1b study is being conducted at six sites in the US. It aims to establish the safety profile of the compound and the recommended dose for further clinical development, as well as an initial assessment of effectiveness. The company also intends to expand the potential of the SEL120 project in new therapeutic areas. Next year, it plans to start the first stage of clinical trials of SEL120 compound in the treatment of solid tumors, including breast cancer.
Acute myeloid leukaemia and STING path agonist
However, Ryvu’s activity is not focused solely on the SEL120. The company will also continue to support its partner Menarini Group in the development of project SEL24/MEN1703. It is the first in its class, oral dual inhibitor of PIM/FLT3 kinases in patients with acute myeloid leukemia. In March 2020, this product completed Phase I of clinical trials. The completion of Phase II is foreseen in 2022.
In addition to clinical projects, Ryvu Therapeutics intends to develop preclinical relationships. He wants to focus on the best in class dual A2A/B antagonist and a small, direct STING track agonist. The entry of at least one of these projects into Phase I of clinical trials is planned for 2022. By the end of 2022, the company also intends to introduce three projects for pre-clinical or advanced characterisation studies, including an HPK1 inhibitor in immunooncology and a SMARCA2 inhibitor in synthetic lethality.
In total, by the end of 2021. Ryvu intends to invest over PLN 220m. Of this, approximately PLN 190m will be allocated to research and development of new anti-cancer therapies. The company intends to raise about PLN 150m from the issue of shares directed to qualified investors. Other sources of project financing will be grants and own resources.
Photo: Ryvu Therapeutics.